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Abstract
Transverse testicular ectopia (TTE) is a rare anomaly in which both testes descend through a single inguinal canal.
We report a case of yolk sac tumor in the ectopic testis of a patient with TTE. A 24-year-old man presented to our
hospital with a left inguinal-mass, right cryptorchidism and elevated alpha-fetoprotein (AFP). A left herniotomy 3
years earlier demonstrated both testes in the left scrotum, one above another positionally. Four months ago, a left
scrotal mass appeared and radical orchiectomy of both testes revealed testicular yolk sac tumor of the ectopic
testis. An enlarging left inguinal-mass appeared 2 months ago and he was referred to our hospital. Laboratory data
showed an elevation of AFP (245.5 ng/ml) and a 46 XY karyotype. He underwent bilateral retroperitoneal lymph
node dissection and simultaneous left inguinal mass dissection. Histopathologic examination revealed a diagnosis
of recurrent yolk sac tumor in the left inguinal mass. The retroperitoneal lymph node was not enlarged and, on
histopathology, was not involved. The patient has now been followed up for 8 months without evidence of
biochemical or radiological recurrence.
Background
Transverse testicular ectopia (TTE), also named crossed
testicular ectopia, is a rare anomaly in which both testes
descend through a single inguinal canal while the opposite
inguinal canal and hemiscrotum are empty. More than
100 cases of TTE have been reported since Von Cenhos-
sek described the first case in 1886[1-3]. As with undes-
cended testis, the ectopic gonads are at increased risk of
malignant transformation [4]. We report a case of yolk sac
tumor in the ectopic testis of a patient with TTE.
Case Presentation
A 24-year-old man, who had fathered a child, presented
to our hospital with a left inguinal-mass (Figure 1), right
cryptorchidism and elevated alpha-fetoprotein (AFP)
(245.5 ng/ml, normal 0.6 to 6.7 ng/ml). He had no family
history of persistent Mullerian duct syndrome or testicu-
lar tumors. His past surgical history included a left her-
niotomy 3 years earlier during which both testes were
demonstrable in the left scrotum, with one located above
the other positionally. Four months ago, a left scrotal
mass appeared and elevated AFP (373.5 ng/ml) was
detected. Carcinoembryonic antigen (CEA) and human
chorionic gonadotropin (HCG) levels were within normal
ranges. Radiological staging prior to management of the
scrotal mass revealed no metastasis. During surgery, the
normal-position testis was found to be invaded by the
ectopic malignant one. Radical orchiectomy of both
testes revealed a yolk sac tumor in the ectopic one. The
AFP level was still high (64.7 ng/ml) after orchiectomy.
An enlarging left inguinal mass appeared 2 months ago
and he was referred to our hospital.
On admission, physical examination revealed a normal
constitution, with secondary sex characteristics and nor-
mal external genital development. His karyotype was 46
XY. Laboratory data showed an elevation of AFP (245.5
ng/ml). CEA and HCG levels, however, were within nor-
mal ranges. Chest x-ray and abdominal CT were normal.
The patient underwent open bilateral modified retroper-
itoneal lymph node dissection (RPLND) and simultaneous
left inguinal mass dissection at our hospital. During opera-
tion, bilateral spermatic cords were found to descend
through the left internal inguinal ring (Figure 2) and no
persistent Mullerian duct structures were observed. Histo-
pathologic examination revealed a diagnosis of yolk sac
tumor in the recurrent left inguinal mass at the spermatic
residual end (Figure 3). The retroperitoneal lymphadeno-
pathy was negative for metastasis. The plasma levels of
AFP had returned to normal at the 3-month postsurgical
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Discussion
TTE is a rare form of testicular ectopia. The clinical
presentation generally includes an inguinal hernia on
one side and a contralateral or sometimes bilateral cryp-
torchidism [5]. In the majority of published reports, the
exact diagnosis was established only during surgical
intervention [6]. Recently, it has been suggested that
magnetic resonance imaging (MRI) would be useful for
preoperative localization of impalpable testis[7]. Laparo-
scopy is useful for both the diagnosis and management
of TTE and its associated anomalies[8].
TTE has been classified into three types on the basis
of associated anomalies: (1) associated with inguinal
hernia alone (40% to 50%); (2) associated with persis-
tent or rudimentary müllerian duct structures (30%);
Figure 1 Left inguinal mass on the CT scan.
Figure 2 Both spermatic cords were found to descend through the left internal inguinal ring.
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lerian remnants (inguinal hernia, hypospadias, pseudo-
hermaphroditism, and scrotal abnormalities) (20%)[2].
According to this classification, our patient would be
designated as a case of type 1 TTE.
Patients with TTE are at increased risk of malignant
transformation, with a 5%-18% overall incidence rate,
similar to the rate of cryptorchidism[4]. There have
been reports of embryonal carcinoma, seminoma, yolk
sac tumor, teratoma and mixed germ cell tumors [9-11].
However, most reported cases of intraabdominal tumors
were in patients with type 2 TTE. To the best of our
knowledge, we are reporting the first case of a scrotal
yolk sac tumor in a patient with type 1 TTE.
Therapeutic approaches for TTE include transseptal
orchiopexy or extraperitoneal transposition of the testis
and a search for müllerian remnants and other anomalies
[2]. However, the malignant potential of these gonads must
be recognized and orchiopexy, even if performed early in
life, does not decrease the risk of malignancy[11]. As most
tumors in this group will occur after puberty, long-term
follow-up is mandatory. Some surgeons suggest that orch-
iectomy should be performed in patients older than 2 years
because orchiopexy offers only limited protection against
future malignancy[11]. In our opinion, for patients who
have not yet reached puberty, orchiectomy is indicated
only for testis that cannot be mobilized to a palpable loca-
tion. For adult patients, dissection of the ectopic testis and
active surveillance of the remnant is recommended.
This patient is classified as having a clinical stage I non-
seminomatous germ cell tumor (NSGCT) of the ectopic
testis. Histopathologic examination revealed a diagnosis of
yolk sac tumor in the recurrent left inguinal mass. Such
patients can be managed by surveillance, primary che-
motherapy or nerve-sparing RPLND.. Surveillance can
spare patients without metastasis from undergoing che-
motherapy or RPLND. However, according to Foster’s
review, approximately 30% of patients with clinical stage I
NSGCT have occult metastases that are difficult to identify
with imaging[12]. In addition, prepubertal testicular neo-
plasms differ greatly from postpubertal lesions. Most pre-
pubertal patients (85%) with yolk sac tumor are stage I at
presentation, compared with only 35% stage I tumors at
presentation of postpubertal patients[13]. Therefore, nerve-
sparing RPLND or platinum-based chemotherapy has a
central role in management of postpubertal adult patients.
Although platinum-based chemotherapy for yolk sac
tumors has produced excellent survival results, its side
effects are not negligible. Raynoud’s phenomenon (25-
30%), ototoxicity (20%), neurotoxicity (15%), and nephro-
toxicity (31%) are some of the common complications
that occur in survivors of testicular cancer [14]. The
advantages of RPLND include the immediate determina-
tion of exact stage, the chance for cure with surgical
removal of involved lymph nodes and the elimination of
the need for monitoring a patient postoperatively with
CT scans. Although the surgery itself is a burden to most
patients, we treated our patient with bilateral modified
RPLND along with excision of the inguinal mass after
discussions with the patient and his wife. No further che-
motherapy was employed because retroperitoneal lymph
nodes showed no metastases.
Figure 3 The resected left inguinal mass with bilateral spermatic cords and retroperitoneal lymph nodes.
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We present a rare case of a scrotal yolk sac tumor in a
patient with type 1 TTE. The diagnosis of TTE should be
considered when unilateral hernia and concurrent cryp-
torchidism of the contralateral side are present. The malig-
nant potential of the ectopic gonads must be recognized
and long-term follow-up is mandatory. For patients who
have not yet reached puberty, orchiopexy is recommended
and orchiectomy is indicated only for testes that cannot be
mobilized to a palpable location. For adult patients, dissec-
tion of the ectopic testis and active surveillance of the
remnant is recommended. For patients with scrotal yolk
sac tumor and type 1 TTE, RPLND, surveillance and adju-
vant chemotherapy are all accepted treatments for long-
term survival after orchiectomy.
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